Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Urup, Thomas, Michaelsen, Signe Regner, Olsen, Lars Rønn, Toft, Anders, Christensen, Ib Jarle, Grunnet, Kirsten, Winther, Ole, Broholm, Helle, Kosteljanetz, Michael, Issazadeh-Navikas, Shohreh, PoulseVolume:
10
Language:
english
Journal:
Molecular Oncology
DOI:
10.1016/j.molonc.2016.05.005
Date:
October, 2016
File:
PDF, 1.22 MB
english, 2016